Stratified medicine in selecting biologics for the treatment of severe asthma.
Curr Opin Allergy Clin Immunol 11(1):58-63 (2011) PMID 21150434
Despite optimal treatment, asthma symptoms in about 5-10% of patients remain poorly controlled. Apart from having an impact on their asthma-related quality of life and adverse effects of the medications used (especially corticosteroids), their severe symptoms also impact healthcare resources due to frequent admission and requirement for intensive medications use. The last decade has seen an improved understanding in the pathophysiology of the complex cellular and molecular networks involved in the inflammatory and immunological phenotype of severe asthma. This knowledge may help providing strategies by which these phenotypes operate and pave the way for drug development and individualized treatment.
DOI: 10.1097/ACI.0b013e3283423245
Version: za2963e q8za7 q8zb6 q8zc5 q8zd5 q8zec q8zf3 q8zge